Many countries have made significant progress in the implementation of World Health Organization recommended preventive chemotherapy strategy, to eliminate lymphatic filariasis (LF). However, pertinent challenges such as the existence of areas of residual infections in disease endemic districts pose... potential threats to the achievements made. Thus, this study was undertaken to assess the importance of these areas in implementation units (districts) where microfilaria (MF) positive individuals could not be found during the mid-term assessment after three rounds of mass drug administration.
more
Infectious Diseases of Poverty (2022) 11:111; With some 134,073,166 people living in endemic communities at risk of infection, Nigeria is the most endemic country in Africa and requires preventive chemotherapy (PC) for a total of 26.3 million persons. The National Schistosomiasis Elimination Program...me (NSCHEP), with the support of international partners, has been implementing PC in Nigeria since 2009 and most recently will need to revise its current strategy (Additional file 1). For example, the new World Health Organization (WHO) guideline has six key recommendations that will dramatically change the implementation of schistosomiasis elimination in endemic countries [3]. However, its impact and programmatic implications will vary from country to country, hence the need for a country-specific analysis. This article discusses these recommendations with specific reference to the challenges and opportunities in Nigeria. We summarise the key pointers in Additional file 1: Box 1 against the six recommendations of the WHO 2022 guideline.
more
A key component of achieving control and elimination of neglected tropical diseases (NTDs) is effective supply chain management of preventive chemotherapy drugs for Mass Drug Administration (MDA) for trachoma, river blindness, lymphatic filariasis, soil-transmitted helminthiasis and schistosomiasis.... This course explains the end-to-end process from planning and submitting donated drug requests through to waste management of expired and unserviceable stock and reverse logistics of unused tablets. It is essential knowledge for all levels of the health system that must work together to implement MDA.
more
Schistosomiasis is an acute and chronic parasitic disease caused by blood flukes (trematode worms) of the genus Schistosoma. Estimates show that at least 251.4 million people required preventive treatment in 2021. Preventive treatment, which should be repeated over a number of years, will reduce and... prevent morbidity. Schistosomiasis transmission has been reported from 78 countries. However, preventive chemotherapy for schistosomiasis, where people and communities are targeted for large-scale treatment, is only required in 51 endemic countries with moderate-to-high transmission.
more
This report represents the WHO-supported NTDs program activities and key performances in 2023. It is categorized into three sections: The first section states on the disease targeted for eradication (Guinea worm disease); the second section is on the
Preventive Chemotherapy (PC)-NTDs (Trachoma, ...Schistosomiasis, Soil Transmitted Helminthiasis, Onchocerciasis and Lymphatic Filariasis) and the third section is focused on the case management NTDs (Leishmaniasis, Leprosy, Human African
Trypanosomiasis, Noma and other skin NTDs).
more
Since the launch of the Global Programme to Eliminate Lymphatic Filariasis (GPELF) in 2000, more than 910 million people have received preventive chemotherapy for lymphatic filariasis (LF) and many thousands have received care for chronic manifestations of the disease. To achieve this, millions of c...ommunity drug distributors (CDDs), community members and health personnel have worked together each year to ensure that at-risk communities receive preventive chemotherapy through mass drug administration (MDA). The successes of 20 y of partnership with communities is celebrated, including the application of community-directed treatment, the use of CDDs and integration with other platforms to improve community access to healthcare. Important challenges facing the GPELF moving forward towards 2030 relate to global demographic, financing and programmatic changes. New innovations in research and practice present opportunities to encourage further community partnership to achieve the elimination of LF as a public health problem. We stress the critical need for community ownership in the current Covid-19 pandemic, to counter concerns in relaunching MDA programmes for LF.
more
This manual summarizes key issues related to the safety of NTD medicines and their administration, with a focus on essential medicines used in mass drug administration (MDA), also called preventive chemotherapy. It can be used as a standalone reference manual, but is intended to be used in conjuncti...on with the accompanying training modules, which provide practical instruction, and the aide-mémoires. Versions of the aide-mémoires and training modules are available respectively for both (i) programme managers and district-level health officials and (ii) community drug distributors and community health workers
more
Advances have been made through expanded interventions delivered through five public health approaches: innovative and intensified disease management; preventive chemotherapy; vector ecology and management; veterinary public health services; and the provision of safe water, sanitation and hygiene. I...n 2015 alone nearly one billion people were treated for at least one disease and significant gains were achieved in relieving the symptoms and consequences of diseases for which effective tools are scarce; important reductions were achieved in the number of new cases of sleeping sickness, of visceral leishmaniasis in South-East Asia and also of Buruli ulcer.
The report also considers vector control strategies and discusses the importance of the draft WHO Global Vector Control Response 2017–2030.
more
ajtmh.20-1538 Volume 104, 6. Mapping is a prerequisite for effective implementation of interventions against neglected tropical diseases (NTDs). Before the accelerated World Health Organization (WHO)/Regional Office for Africa (AFRO) NTD Mapping Project was initiated in 2014, mapping efforts in man...y countries were frequently carried out in an ad hoc and nonstandardized fashion. In 2013, there were at least 2,200 different districts (of the 4,851 districts in the WHO African region) that still required mapping, and in many of these districts, more than one disease needed to be mapped. During its 3-year duration from January 2014 through the end of 2016, the project carried out mapping surveysfor one ormore NTDs in at least 2,500 districts in 37 African countries. At the end of 2016, most (90%) of the 4,851 districts had completed the WHO-required mapping surveys for the five targeted Preventive Chemotherapy (PC)-NTDs, and the impact of this accelerated WHO/AFRO NTD Mapping Project proved to be much greater than just the detailed mapping results themselves. Indeed, the AFRO Mapping
Project dramatically energized and empowered national NTD programs, attracted donor support for expanding these programs, and developed both a robust NTD mapping database and data portal. By clarifying the prevalence and burden
of NTDs, the project provided not only the metrics and technical framework for guiding and tracking program implementation and success but also the research opportunities for developing improved diagnostic and epidemiologic sampling tools for all 5 PC-NTDs—lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiasis, and trachoma.
more
Integrating neglected tropical diseases into global health and development: fourth WHO report on neglected tropical diseases evaluates the changing global public health landscape; assesses progress towards the 2020 targets; and considers the possible core elements of a strategic vision to integratin...g neglected tropical diseases into the 2030 Agenda of the Sustainable Development Goals.
Advances have been made through expanded interventions delivered through five public health approaches: innovative and intensified disease management; preventive chemotherapy; vector ecology and management; veterinary public health services; and the provision of safe water, sanitation and hygiene. In 2015 alone nearly one billion people were treated for at least one disease and significant gains were achieved in relieving the symptoms and consequences of diseases for which effective tools are scarce; important reductions were achieved in the number of new cases of sleeping sickness, of visceral leishmaniasis in South-East Asia and also of Buruli ulcer.
The report also considers vector control strategies and discusses the importance of the draft WHO Global Vector Control Response 2017–2030. It argues that veterinary public health requires a multifaceted approach across the human–animal interface as well as a multisectoral programme of work to protect and improve the physical, mental and social well-being of humans, including veterinary, water, sanitation and hygiene.
Integration of activities and interventions into broader health systems is crucial, and despite challenges, has the potential to accelerate progress towards universal health coverage while advancing the 2030 Agenda.
In short, this report drives the message home that “no one must be left behind”.
more
Lancet Infectious Diseases Volume 22, Issue 11e327-e335.
In February, 2022, WHO published new guidelines with six recommendations to update the global public health strategy against schistosomiasis, including expansion of preventive chemotherapy eligibility from the predominant group of school-age...d children to all age groups (2 years and older), lowering the prevalence threshold for annual preventive chemotherapy, and increasing the frequency of treatment. This Review, written by the 2018-2022 Schistosomiasis Guidelines Development Group and its international partners, presents a summary of the new WHO guideline recommendations for schistosomiasis along with their historical context, supporting evidence, implications for public health implementation, and future research needs.
more
To eliminate lymphatic filariasis (LF) by 2020, the World Health Organization (WHO) has launched a campaign against the disease. Since the launch in 2000, significant progress has been made to achieve this ambitious goal. In this article we review the progress and status of the LF programme in Afric...a through the WHO neglected
tropical diseases preventive chemotherapy databank, the Expanded Special Project for Elimination of Neglected Tropical Diseases (ESPEN) portal and other publications. In the African Region there are 35 countries endemic for LF. The Gambia was reclassified as not requiring preventive chemotherapy in 2015, while Togo and Malawi eliminated LF as a public health problem in 2017 and 2020, respectively. Cameroon discontinued mass drug administration (MDA) and transitioned to post-MDA surveillance to validate elimination. The trajectory of coverage continues to accelerate; treatment coverage increased from 0.1% in 2000 to 62.1% in 2018. Geographical coverage has also significantly increased, from 62.7% in 2015 to 78.5% in 2018. In 2019, 23 of 31 countries requiring MDA achieved 100% geographic coverage. Although much remains to be done, morbidity management and disability prevention services have steadily increased in recent years. Vector control interventions conducted by other programmes, particularly malaria vector control, have had a profound effect in stopping transmission in some endemic countries in the region. In conclusion, significant progress has been made in the LF programme
in the region while we identify the key remaining challenges in achieving an Africa free of LF.
more
This website contains information about cancer in english and arabic on different topics (breast cancer, bowel cancer, brain tumours, cervical cancer, ovarian cancer, prostate cancer, chemotherapy, surgery, radiotherapy, prevention and much more). The material is also available in other languages (c...hinese, greek, italian, macedonian, spanish, vietnamese, mandarin)
more
La schistosomiase est une parasitose aiguë et chronique provoquée par des vers (trématodes) du genre Schistosoma. Selon les estimations, au moins 251,4 millions de personnes avaient besoin d’un traitement préventif en 2021. Le traitement préventif, qui devrait être renouvelé pendant un cert...ain nombre d’années, permettra de réduire et de prévenir la morbidité. La transmission de la schistosomiase est avérée dans 78 pays. Cependant, la chimioprophylaxie de la maladie, dont le but est de traiter à grande échelle les populations et les communautés, n’est nécessaire que dans 51 pays d’endémie où la transmission est de modérée à forte.
more
داء البلهارسيات هو مرض طفيلي حاد ومزمن تسبّبه الديدان المثقوبة الدموية (المثقوبات) من جنس البلهارسية. وتشير التقديرات إلى أن 251.4 مليون شخص على الأقل كانوا بحاجة إلى ...لعلاج الوقائي من داء البلهارسيات في عام 2021. ومن شأن العلاج الوقائي، الذي ينبغي تكراره على مدى عدة سنوات، أن يحد من المراضة ويمنعها. وقد أُبلغ عن سريان المرض في 78 بلداً. ومع ذلك، فإن العلاج الكيميائي الوقائي لداء البلهارسيات الذي يُستهدف فيه الأشخاص والمجتمعات المحلية بالعلاج على نطاق واسع، لا يلزم إلا في 51 بلداً موطوناً يشهد مستويات سريان المرض المتوسطة أو العالية.
more
La esquistosomiasis es una enfermedad parasitaria aguda y crónica causada por duelas sanguíneas (trematodos) del género Schistosoma. Se calcula que al menos 251,4 millones de personas necesitaron tratamiento profiláctico en 2021. El tratamiento profiláctico, que se debería repetir durante algu...nos años, permite reducir y prevenir la morbilidad. Hay constancia de la transmisión de la enfermedad en 78 países. Sin embargo, la quimioprofilaxis para la esquistosomiasis, en la que se aplica un tratamiento a gran escala a personas y comunidades, solamente se requiere en 51 países en los que la enfermedad es endémica y tienen una transmisión de moderada a alta.
more
Шистосомоз является острой и хронической паразитарной болезнью, вызываемой кровяными сосальщиками (трематодными червями) из рода Schistosoma. В 2021 г. количество нуждаю...ихся в профилактическом лечении шистосомоза оценивалось на уровне не менее 251,4 млн человек. Профилактическое лечение, которое необходимо повторять через несколько лет, снижает и предотвращает заболеваемость шистосомозом. Передача шистосомоза регистрируется в 78 странах. Однако профилактическая химиотерапия в рамках широкомасштабного лечения шистосомоза среди людей и общин требуется только в 51 эндемичной стране с умеренными и высокими показателями передачи инвазии.
more
On 15–16 December 2020, WHO and the Medicines for Malaria Venture co-convened a technical consultation to consider the preferred product characteristics (PPCs) for drugs used in malaria chemoprevention. The main goal of the technical consultation was to agree on the most important PPCs for drugs t...o protect populations from malaria (chemoprevention), while considering relevant measures of efficacy and the safety data needed to support WHO policy recommendations.
more
Review
S Afr Med J 2014;104(3):174-177. DOI: 10.7196/SAMJ.7968